Aldolase, designated enzymatically as fructose-bisphosphate aldolase, represents a central biocatalytic linchpin operating at the very heart of cellular bioenergetics. Found ubiquitously across phylogenetic kingdoms, this essential enzyme governs a reversible cleavage mechanism within glycolysis and gluconeogenesis, dictating how mammalian cells partition chemical energy derived from carbohydrates. Beyond its foundational kinetic profile, aldolase serves as an indispensable clinical biomarker in neuromuscular and hepatic diagnostics, while contemporary molecular biology highlights its multifaceted roles in cytoskeletal architecture, cellular signaling, and malignant transformation.
Aldolase (ALS)
1. Concise Definition
Aldolase (EC 4.1.2.13), systematically known as D-fructose-1,6-bisphosphate D-glyceraldehyde-3-phosphate-lyase, is a pivotal metabolic enzyme belonging to the lyase class that catalyzes the reversible cleavage of fructose 1,6-bisphosphate (FBP) into two distinct triose phosphates: dihydroxyacetone phosphate (DHAP) and D-glyceraldehyde 3-phosphate (G3P). In specialized tissues, it similarly converts fructose 1-phosphate into dihydroxyacetone phosphate and glyceraldehyde, bridging dietary fructose metabolism with core energetic cascades.
In eukaryotic physiology, aldolase functions as a homotetrameric biocatalyst that operates without consuming adenosine triphosphate (ATP), playing a bidirectional regulatory role in both degradative glycolysis and anabolic gluconeogenesis. Clinically termed serum aldolase (ALS), its quantification provides acute diagnostic insight into sarcolemmal integrity, skeletal muscle pathology, and inherited inborn errors of carbohydrate metabolism.
2. Etymology & Linguistic Origin
The term aldolase is an etymological blend derived from organic chemistry nomenclature and classical linguistic roots. The prefix aldol- contracts the words aldehyde and alcohol, referencing an aldol condensation reaction—a term originally coined in 1872 by the French chemist Charles-Adolphe Wurtz to describe the beta-hydroxyaldehyde product obtained through self-condensation of acetaldehyde. The chemical root aldehyde itself was coined by Justus von Liebig as an abbreviation of the Latin alcohol dehydrogenatus (“dehydrogenated alcohol”).
The suffix -ase derives from the Greek -ασις (applied as an arbitrary linguistic marker for biological ferments), formally introduced into biochemistry in 1833 by Anselme Payen and Jean-François Persoz with their discovery of diastase. The compound noun entered the international scientific lexicon in the 1930s when pioneering enzymologists identified the biological catalyst capable of mediating reversible aldol-type cleavages in cellular extracts.
3. Pronunciation & Grammatical Form
Pronunciation: The standard academic pronunciation in International Phonetic Alphabet (IPA) transcription is /ˈæl.dəˌleɪs/ or /ˈæl.dəˌleɪz/ in General American English, and /ˈæl.dəʊ.leɪs/ in Received Pronunciation. Stress resides prominently upon the initial syllable.
Grammatical Form: Grammatically, aldolase is a non-count (uncountable) common biological noun when denoting the catalytic substance in abstract, but functions as a countable noun when distinguishing structural isoforms, genetic alleles, or evolutionary homologs (e.g., “the mammalian aldolases”). Common biomedical abbreviations include ALS (frequently utilized in clinical chemistry panels, though caution is required to prevent confusion with amyotrophic lateral sclerosis) and ALDO (predominant in genomic nomenclature, encompassing ALDOA, ALDOB, and ALDOC).
4. Detailed Conceptual Explanation
To fully grasp the bioenergetic prominence of aldolase, one must examine its catalytic mechanism, evolutionary stratification, and structural thermodynamics. At the cellular level, carbohydrate oxidation requires the six-carbon hexose skeleton of glucose to be destabilized and cleaved into three-carbon units. Following phosphorylation by hexokinase and phosphofructokinase-1, fructose 1,6-bisphosphate enters the catalytic pocket of aldolase. The enzyme shifts the equilibrium of this reaction, severing the C3–C4 carbon-carbon bond via an aldol cleavage mechanism to generate one molecule of dihydroxyacetone phosphate and one molecule of glyceraldehyde 3-phosphate.
Nature has evolved two distinct evolutionary solutions to achieve this bond cleavage, dividing aldolases into two structurally and mechanistically disparate categories: Class I and Class II. Class I aldolases are expressed ubiquitously in animals, plants, and higher eukaryotes. They utilize an active-site lysine residue (specifically Lys-229 in mammalian Aldolase A) to form a covalent, protonated Schiff base (aldimine intermediate) with the carbonyl carbon of the substrate. This intermediate acts as an electron sink, stabilizing the carbanion generated during carbon-carbon scission. Conversely, Class II aldolases, found primarily in bacteria, yeast, and fungi, do not form an aldimine intermediate; instead, they operate as metalloenzymes that depend strictly on a bivalent active-site zinc cation (Zn²⁺) to coordinate the substrate’s carbonyl group and polarize the bond.
Mammalian Class I aldolase exists predominantly as a stable homotetramer with a molecular weight of approximately 160 kDa (composed of four identical ~40 kDa subunits). Structural biology reveals that each subunit is folded into a classic TIM-barrel motif (an alpha/beta barrel containing eight parallel beta-strands encircled by eight alpha-helices). The active center is buried within the barrel core, shielded from the bulk solvent to facilitate precise electrostatic interactions with the phosphate moieties of the hexose substrate.
Crucially, aldolase does not operate solely as an isolated metabolic cog. Modern structural enzymology demonstrates that aldolase undergoes dynamic supramolecular organization, assembling into temporary “metabolons” with neighboring enzymes, such as phosphofructokinase, glyceraldehyde-3-phosphate dehydrogenase, and triosephosphate isomerase. By channeling intermediates directly from one catalytic cleft to the next, aldolase minimizes substrate diffusion times, circumvents the dilution of metabolic flux, and protects reactive triose intermediates from non-enzymatic degradation or toxic methylglyoxal formation.
5. Historical Development
The discovery and characterization of aldolase run parallel to the formulation of modern bioenergetics in the early twentieth century. In 1934, German biochemists Otto Meyerhof and Karl Lohmann isolated a thermolabile agent from mammalian skeletal muscle extracts capable of cleaving hexose bisphosphates into triose phosphates, christening this activity Zymohexase. Subsequent analytical refinements revealed that Zymohexase was not a single entity, but an enzymic consortium consisting of aldolase and triosephosphate isomerase.
During the late 1930s and 1940s, Otto Warburg and Walter Christian successfully purified aldolase from yeast, noting significant functional differences compared to muscle-derived extracts. Warburg demonstrated that the yeast enzyme was inhibited by chelating agents such as pyrophosphate and alpha,alpha-dipyridyl, whereas the mammalian muscle enzyme was resilient. This critical divergence laid the conceptual groundwork for the formal taxonomic bifurcation into Class I (metal-independent) and Class II (metallo-dependent) aldolases, which was definitively elucidated by William Rutter and colleagues in the 1960s.
The mid-to-late twentieth century brought substantial insights into the tissue-specific polymorphism of aldolase. Through pioneering electrophoretic and immunological studies led by researchers such as B.L. Horecker and William Rutter, three structurally distinct mammalian isozymes were resolved: Aldolase A (isolated from muscle), Aldolase B (isolated from liver), and Aldolase C (isolated from the brain). With the advent of recombinant DNA technology in the 1980s, the human genes ALDOA, ALDOB, and ALDOC were mapped and sequenced, revealing clear chromosomal dispersion and tightly coordinated transcriptional control.
In the twenty-first century, high-resolution X-ray crystallography and cryo-electron microscopy have mapped the quaternary architecture of aldolase to atomic resolution. Concurrently, proteomics has revealed non-canonical “moonlighting” functions for aldolase, demonstrating that this classic metabolic driver participates directly in structural cytoskeletal scaffolding, endocytosis, and cell survival pathways.
6. Theoretical Foundations
The operational framework of aldolase is rooted in three major biochemical paradigms: thermodynamic reversibility, isozyme specialization, and non-canonical “moonlighting” multifunctionality.
Thermodynamic Reversibility and Metabolic Flux: In the classic Embden-Meyerhof-Parnas glycolytic model, aldolase occupies a reversible junction. Under standard physiological conditions, the standard Gibbs free energy change (ΔG°’) of the cleavage reaction is distinctly endergonic (approximately +23.8 kJ/mol). However, inside the living cytosol, the actual free energy change (ΔG) hovers near zero (varying between -1.3 and +0.5 kJ/mol) because the downstream products—DHAP and G3P—are continuously and rapidly cleared by triosephosphate isomerase and glyceraldehyde 3-phosphate dehydrogenase. This close thermodynamic equilibrium means aldolase is poised to shift its net flux instantaneously between catabolism (glycolysis) and anabolism (gluconeogenesis) in response to cellular energy charge and substrate availability.
Isozymic Divergence and Substrate Specificity: The theoretical basis of mammalian aldolase relies heavily on tissue-specific evolutionary adaptation. The three isozymic variants exhibit starkly divergent kinetic properties, specifically regarding their affinity for fructose 1,6-bisphosphate relative to fructose 1-phosphate (F1P):
- Aldolase A: Demonstrates a high affinity and catalytic efficiency for FBP (cleaving FBP ~50 times faster than F1P), optimizing it for high-throughput glycolytic burst activity in contracting skeletal muscle.
- Aldolase B: Exhibits approximately equal catalytic activity toward FBP and F1P (a ratio of ~1:1), uniquely enabling the liver to assimilate large dietary fluxes of fructose into downstream central metabolism via the fructolysis pathway.
- Aldolase C: Displays an intermediate kinetic profile, fine-tuned to maintain continuous baseline glycolytic requirements within central nervous system astrocytes and specialized Purkinje neurons.
The “Moonlighting” Enzyme Paradigm: In contemporary molecular cell biology, aldolase serves as a prime exemplar of enzyme moonlighting—wherein a protein executes distinct biological tasks unrelated to its canonical catalytic activity. Theoretical models describe aldolase as a structural anchor that interacts physically with filamentous actin (F-actin), the Wnt-signaling scaffolding machinery, the glucose transporter GLUT4, and the proton-translocating vacuolar ATPase (V-ATPase). These non-enzymatic interactions demonstrate that the cell exploits the geometric conformation and abundance of aldolase to cross-regulate metabolic rate, endosomal acidification, vesicular trafficking, and cytoskeletal stability.
7. Key Components, Types & Dimensions
Mammalian aldolases encompass three primary genetic isoforms alongside their functional molecular domains:
- Aldolase A (Muscle Isoform; encoded by ALDOA on chromosome 16p11.2): Expressed predominantly in adult skeletal muscle, erythrocytes, and vascular smooth muscle. Its primary dimension is sustaining rapid glycolytic turnover under hypoxic or high-demand conditions. Dysregulation is strongly implicated in hemolytic anemia, myopathy, and tumor metastasis.
- Aldolase B (Liver Isoform; encoded by ALDOB on chromosome 9q31.1): Localized primarily within hepatocytes, renal tubular epithelia, and intestinal enterocytes. It possesses the unique catalytic competence to process fructose 1-phosphate efficiently. Inactivating mutations in this isoform lead directly to the clinical manifestations of Hereditary Fructose Intolerance.
- Aldolase C (Brain Isoform; encoded by ALDOC on chromosome 17q11.2): Predominantly synthesized within the central nervous system, particularly in cerebellar Purkinje cells and astroglial networks. Aldolase C typically forms hybrid tetrameric configurations with Aldolase A (e.g., A3C1, A2C2, A1C3) in neural tissues, balancing baseline glycolytic flow with localized neuroprotection.
- The Catalytic Core (TIM-Barrel Subunit): An eight-stranded alpha/beta barrel containing the Schiff-base forming lysine (Lys-229), alongside critical coordinating residues including Asp-33, Arg-42, Lys-146, and Arg-303, which collectively form the phosphate-binding pockets for the C1 and C6 ester groups of the hexose substrate.
- Structural Regulatory Motifs: The flexible C-terminal arm, which modulates substrate specificity and catalytic speed. Truncation or phosphorylation of this flexible tail markedly reduces catalytic turnover for FBP while preserving or altering secondary moonlighting functions.
8. Examples & Illustrative Cases
To contextualize the physiological and clinical impact of aldolase, consider the following real-world clinical and biochemical scenarios:
Case 1: Hereditary Fructose Intolerance (ALDOB Deficiency): A six-month-old infant undergoes dietary weaning, introducing pureed fruits containing sucrose and fructose. Within thirty minutes of feeding, the infant exhibits severe diaphoresis, pallor, persistent vomiting, tremors, and profound lethargy. Emergency biochemical evaluation reveals profound hypoglycemia, severe metabolic acidosis, and markedly elevated serum transaminases. Genetic testing uncovers a homozygous missense mutation (A149P) within the ALDOB gene. In this disorder, defective Aldolase B cannot cleave fructose 1-phosphate, causing toxic intrahepatic accumulation of F1P. This sequestering of free cellular inorganic phosphate rapidly depletes ATP, suppressing glycogen phosphorylase and fructose 1,6-bisphosphatase. The result is an acute block of both glycogenolysis and gluconeogenesis, producing catastrophic hypoglycemia.
Case 2: Diagnostic Utility in Statin-Induced Myopathy: A 58-year-old patient with hypercholesterolemia receiving high-dose atorvastatin presents with progressive, proximal lower-limb myalgia and muscle weakness. Serum testing reveals a mild elevation in creatine kinase (CK) at twice the upper limit of normal, alongside a fivefold elevation in serum aldolase (ALS). Because aldolase is expressed in high concentrations throughout structural myofibers, elevated serum ALS can sometimes serve as an early, highly sensitive indicator of sarcolemmal injury, prompting clinicians to adjust pharmacological therapies before rhabdomyolysis or irreversible muscular damage ensues.
Case 3: Metabolic Reprogramming in Oncogenesis (The Warburg Effect): In a patient diagnosed with non-small cell lung carcinoma (NSCLC), RNA sequencing of the biopsied tumor reveals severe transcriptional upregulation of ALDOA, driven by the hypoxia-inducible factor 1-alpha (HIF-1α) axis. The hyper-expression of Aldolase A accelerates the cleavage of FBP, sustaining rapid glycolytic flux even in poorly vascularized, oxygen-depleted microenvironments. Concurrently, non-catalytic Aldolase A interacts with actin filaments to promote cytoskeletal remodeling, driving accelerated cell motility, invasiveness, and resistance to standard apoptotic stimuli.
9. Measurement & Assessment
Evaluating aldolase encompasses both enzymatic activity quantification in circulating serum and modern molecular-genetic diagnostic profiling.
Enzymatic Spectrophotometric Assay: Serum aldolase (ALS) activity is classically determined through a coupled enzymatic reaction monitored via ultraviolet (UV) spectrophotometry. In this assay, exogenous substrate (fructose 1,6-bisphosphate) is introduced into the patient’s serum sample. Endogenous aldolase cleaves FBP into DHAP and G3P. The auxiliary enzymes triosephosphate isomerase (TPI) and glycerol-3-phosphate dehydrogenase (GDH) are supplied in excess, alongside reduced nicotinamide adenine dinucleotide (NADH). As DHAP is converted to glycerol 3-phosphate, NADH is concurrently oxidized to NAD⁺. The rate of decreasing absorbance at 340 nm is directly proportional to aldolase catalytic activity in the sample.
Reference Intervals and Specimen Integrity: For healthy adult populations, standard reference intervals for total serum aldolase typically fall between 1.0 and 7.5 U/L (units per liter), depending on assay methodology and laboratory calibration. Because erythrocytes contain high concentrations of Aldolase A, even subtle in vitro hemolysis invalidates the test by falsely elevating measured serum activity. Consequently, unhemolyzed serum must be separated promptly from clot matrices to guarantee diagnostic validity.
Isozyme Analysis and Molecular Diagnostics: When total serum aldolase elevation is ambiguous, isozyme separation can be achieved via agarose gel electrophoresis or ion-exchange chromatography. In pediatric medicine, suspected metabolic defects such as Hereditary Fructose Intolerance bypass invasive liver biopsies in favor of targeted high-throughput genomic sequencing of the ALDOB locus, pinpointing common pathogenic alleles (such as A149P, A174D, and N334K).
10. Applications & Practical Significance
The study and clinical evaluation of aldolase span multiple critical disciplines across modern medicine and biotechnology:
Neuromuscular and Rheumatological Diagnostics: Serum aldolase serves as a sensitive diagnostic biomarker for assessing acute myopathic destruction. In conditions such as polymyositis, dermatomyositis, and Duchenne muscular dystrophy, sarcolemmal integrity degrades, causing intracellular enzymes to leak into the interstitial fluid and bloodstream. Importantly, in a defined subset of patients with chronic or atypical polymyositis, serum creatine kinase (CK) levels may occasionally normalize or fluctuate, while serum aldolase remains persistently elevated. Measuring aldolase alongside CK helps rheumatologists monitor disease activity and evaluate responses to immunosuppressive therapy.
Pediatric Metabolic Medicine: In medical genetics, understanding Aldolase B kinetics is central to managing Hereditary Fructose Intolerance (HFI). Eliminating dietary fructose, sucrose, and sorbitol resolves acute systemic toxicity and prevents chronic hepatic cirrhosis and renal Fanconi-like tubular dysfunction, underscoring how a single enzyme deficiency requires lifelong, targeted medical nutrition therapy.
Oncology and Cancer Therapeutics: Because tumor cells rely heavily on aerobic glycolysis (the Warburg effect), Aldolase A has emerged as an attractive candidate for targeted therapeutic inhibition. Preclinical studies indicate that small-molecule inhibitors targeting the ALDOA active site or disrupting its interaction with actin can slow cancer cell proliferation, impair migratory mechanics, and restore sensitivity to standard chemotherapeutic drugs.
Industrial Biotechnology and Biocatalysis: Outside clinical medicine, recombinant aldolases are powerful chiral catalysts in synthetic organic chemistry. Due to their strict stereospecificity, engineered aldolases are used to synthesize complex carbohydrates, rare sugars, unnatural amino acids, and novel antiviral nucleosides under environmentally benign, aqueous reaction conditions without cumbersome protecting-group strategies.
11. Research & Empirical Evidence
Over the past two decades, rigorous empirical research has fundamentally redefined aldolase from a static metabolic intermediary into a dynamically regulated biological coordinator.
The Muscle-Damage Concordance Studies: Multiple clinical cohorts have validated the utility of serum aldolase across heterogeneous muscular pathologies. A landmark retrospective cohort study by Casciola-Rosen et al. demonstrated that measuring serum aldolase alongside CK substantially enhances diagnostic sensitivity in inflammatory myopathies, showing that elevated aldolase frequently correlates with perivascular inflammation and cutaneous manifestations even when CK levels remain within baseline parameters.
Structural Scaffolding and Moonlighting Investigations: Biochemical investigations led by Ritterson Lew and colleagues revealed that Aldolase A binds actin filaments with high affinity, directly cross-linking cytoskeletal networks. Subsequent cellular studies confirmed that aldolase acts as an enzymatic glucose sensor: during high glucose availability, aldolase remains uncoupled from the cytoskeleton to maximize catalytic flux, whereas under glucose deprivation, it associates with structural proteins and interacts with the AMP-activated protein kinase (AMPK) complex, triggering downstream protective autophagic pathways.
Oncological Translational Research: In oncology, comprehensive transcriptomic screens across colorectal, pancreatic, and non-small cell lung carcinomas have revealed consistent ALDOA overexpression. Research published by Ji et al. demonstrated that genetic knockdown of ALDOA significantly inhibits tumor proliferation and arrests cell cycle progression in G1/S phases, proving that aldolase activity is rate-limiting for the aggressive energy requirements of these malignancies.
12. Cultural & Cross-Cultural Considerations
While the enzymatic mechanics of aldolase are biochemically invariant across the human species, the clinical significance of aldolase mutations intersects with cultural, regional, and dietary variations worldwide.
The prevalence of pathogenic ALDOB variants displays distinct geographic and ethnic clustering. The most common mutation, A149P, exhibits a carrier frequency of roughly 1 in 120 individuals of Northern and Western European descent, whereas it is markedly less prevalent in East Asian and Sub-Saharan African populations. Consequently, clinical screening protocols and institutional awareness of Hereditary Fructose Intolerance are more established in European pediatric centers, whereas diagnosing the disorder in non-Western clinical environments often requires high suspicion due to lower regional incidence.
Furthermore, cultural dietary compositions profoundly influence the phenotypic expression and clinical severity of Aldolase B deficiency. In industrialized societies with widespread consumption of high-fructose corn syrup, sucrose, and processed sweeteners, undiagnosed infants and adults face constant exposure to metabolic triggers. Conversely, in regions relying primarily on unprocessed, low-fructose staple carbohydrates (such as non-sweetened rice or cassava), individuals harboring heterozygous or milder homozygous ALDOB mutations may remain subclinical or undiagnosed until adulthood, manifesting only mild, self-directed dietary aversions to sweet foods.
13. Criticisms, Debates & Limitations
Despite its long-established role in clinical diagnostics, evaluating serum aldolase remains an active subject of debate within clinical pathology and diagnostic rheumatology.
The Question of Diagnostic Specificity: The primary critique leveled against total serum aldolase is its lack of organ specificity. Because Aldolase A is widely distributed throughout skeletal muscle, red blood cells, and vascular walls, and Aldolase B is expressed in hepatic and renal parenchyma, an elevated serum aldolase value can reflect diverse, unrelated pathologies. Marked elevations occur not only in myositis, but also in acute viral hepatitis, hepatic infarction, progressive muscular dystrophies, myocardial infarction, and systemic hematologic hemolysis. Consequently, many contemporary clinical laboratories argue that serum aldolase is redundant when more tissue-specific markers, such as creatine kinase (CK-MM) for muscle and alanine aminotransferase (ALT) for liver, are readily available.
The “CK-Negative Myopathy” Controversy: Conversely, rheumatologists debate the wisdom of retiring aldolase from standard diagnostic panels. Proponents cite documented presentations of “hypomyopathic dermatomyositis” and statin-induced necrotizing autoimmune myopathy where serum CK levels paradoxically remain normal or marginally elevated, but serum aldolase spikes alongside clinical disease activity. Critics counter that elevated aldolase in these cases may simply reflect localized fasciitis or low-grade erythrocyte fragility rather than definitive myofibrillar necrosis, arguing for standardized diagnostic protocols before drawing therapeutic conclusions.
Targeting Aldolase in Cancer: In the therapeutic arena, targeting aldolase directly presents significant translational challenges. Because Aldolase A is essential for systemic glycolysis—particularly in erythrocytes, which depend exclusively on this pathway for ATP generation—developing systemic small-molecule aldolase inhibitors risks inducing severe hemolytic anemia and broad metabolic toxicity. Thus, cancer researchers focus on disrupting cancer-specific protein-protein interactions rather than applying unselective catalytic inhibitors.
14. Related Terms & Distinctions
To avoid diagnostic and biochemical confusion, aldolase must be clearly distinguished from related enzymes, substrates, and diagnostic markers:
- Creatine Kinase (CK): A kinase that catalyzes the reversible transfer of a phosphate group between ATP and phosphocreatine. Unlike aldolase, CK is not an intermediate glycolytic enzyme; it operates as an energy buffer. CK-MM is far more specific to skeletal muscle tissue than total aldolase.
- Lactate Dehydrogenase (LDH): A terminal glycolytic oxidoreductase that interconverts pyruvate and lactate while cycling NADH/NAD⁺. Like aldolase, LDH is ubiquitously distributed and leaks into serum during tissue necrosis, but it operates at the terminus of glycolysis rather than at the hexose-cleavage stage.
- Triosephosphate Isomerase (TPI): The enzyme acting immediately downstream of aldolase, catalyzing the rapid, reversible isomerization between dihydroxyacetone phosphate (DHAP) and glyceraldehyde 3-phosphate (G3P).
- Phosphofructokinase-1 (PFK-1): The key rate-limiting, highly regulated glycolytic kinase that phosphorylates fructose 6-phosphate into fructose 1,6-bisphosphate, directly generating the primary physiological substrate utilized by aldolase.
- Amyotrophic Lateral Sclerosis (ALS): A fatal neurodegenerative disorder affecting motor neurons. While sharing the clinical acronym “ALS” with aldolase in laboratory ordering systems, it has no direct biological or pathological connection to the enzyme itself.
15. Summary / Key Takeaways
Aldolase (ALS) remains one of the foundational biocatalysts in cellular metabolism, serving as the definitive enzymatic engine that cleaves six-carbon hexose bisphosphates into the three-carbon triose building blocks that drive downstream ATP synthesis. Divided into distinct structural classes and tissue-specific mammalian isozymes (Aldolase A in muscle, Aldolase B in liver, and Aldolase C in the brain), this enzyme balances metabolic requirements across diverse physiologic states. In modern clinical practice, quantifying serum aldolase provides valuable diagnostic and monitoring data for inflammatory myopathies, neuromuscular degenerations, and inborn errors of carbohydrate metabolism such as Hereditary Fructose Intolerance. As ongoing research continues to uncover its non-canonical moonlighting roles in cytoskeletal dynamics, cell signaling, and oncogenesis, aldolase stands as both a classic metabolic driver and an active participant in cellular homeostasis.
References
- Casciola-Rosen, L., Hall, J. C., Mammen, A. L., Antony, R. L., & Rosen, A. (2012). Isolated elevation of aldolase in the presence of normal creatine kinase in dermatomyositis: A marker of fascial involvement? Arthritis Care & Research, 64(4), 584–590. https://doi.org/10.1002/acr.21583
- Chang, Y. C., Yang, Y. C., Tien, C. P., Yang, C. J., & Hsiao, M. (2018). Roles of aldolase family isozymes in gastric cancer and other malignancies. World Journal of Gastroenterology, 24(34), 3848–3859. https://doi.org/10.3748/wjg.v24.i34.3848
- Geffner, M. E., & Lippe, B. M. (1982). Hereditary fructose intolerance: A review of its clinical and biochemical features. American Journal of Diseases of Children, 136(6), 542–546. https://doi.org/10.1001/archpedi.1982.03970420066018
- Kim, D. W., & Dang, C. V. (2006). Multifaceted roles of glycolytic enzymes in cellular homeostasis. Cell Cycle, 5(18), 2056–2060. https://doi.org/10.4161/cc.5.18.3283
- Rutter, W. J. (1964). Evolution of aldolase. Federation Proceedings, 23(6), 1248–1257. https://pubmed.ncbi.nlm.nih.gov/14234057/